Business ❯ Pharmaceutical Industry ❯ Generic Drugs

Market Competition

Pricing Strategies Novo Nordisk Cost Reduction Strategies Drug Pricing Indian Market Cost Reduction Copaxone

Glenmark Settles for $29.6 Million Over Alleged Generic Drug Price Conspiracy

The settlement requires Glenmark to cooperate with ongoing multistate antitrust actions, implement compliance reforms, and make money available for consumer claims covering purchases from May 2009 through December 2019.

12 ARTICLES

3mo ago

Brazil’s Superior Court of Justice Rejects Semaglutide Patent Extension, Paving Way for 2026 Generics

15 ARTICLES

9mo ago

FDA Proposes Faster Biosimilar Approvals by Dropping Routine Human Trials

8 ARTICLES

last yr.

EU Fines Teva $503 Million for Blocking MS Drug Competition

Market Competition

Glenmark Settles for $29.6 Million Over Alleged Generic Drug Price Conspiracy

India’s Generic Semaglutide Wave Eats Into Mounjaro’s Lead as Novo Holds Share

Semaglutide Patent Expires in Brazil, Opening Door to Lower-Cost Rivals

Semaglutide Patents Lapse in India and China as Safety Scrutiny Rises

India Readies Dozens of Semaglutide Generics as Ozempic Patent Nears Expiry

Brazil’s Superior Court of Justice Rejects Semaglutide Patent Extension, Paving Way for 2026 Generics

FDA Proposes Faster Biosimilar Approvals by Dropping Routine Human Trials

EU Fines Teva $503 Million for Blocking MS Drug Competition